E-Prescribing Market (By Product: Solutions, Services; By Delivery Mode; By End-use; By Usage Methods; By Substances; By Specialties) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2023-2032

The global e-prescribing market was valued at USD 2.9 billion in 2022 and it is predicted to surpass around USD 31.23 billion by 2032 with a CAGR of 26.83% from 2023 to 2032.

E-Prescribing Market Size 2023 to 2032

Key Pointers

  • The solutions segment led the market and accounted for the largest global revenue share in 2022.
  • The services segment is anticipated to demonstrate the fastest growth rate of over 29.03% over the forecast period.
  • The web/cloud-based segment held the largest market share in 2022.
  • The on-premise segment is anticipated to witness the highest growth rate of about 26.94% during the projected period.
  • The hospitals segment held the largest market share of more than 35.03% in 2022.
  • The pharmacy segment is expected to expand at the fastest CAGR of about 27.02% from 2023 to 2032.
  • The handheld segment held the largest market share of the global market in 2022.
  • The computer-based devices segment is anticipated to grow at a notable rate of about 26.04% in the near future.
  • The controlled substances segment held the largest share of the market in 2022.
  • The non-controlled substances segment is anticipated to grow at the fastest rate of around 28.06% over the projected period.
  • The sports medicine segment held the largest market share of more than 20.13% in 2022.
  • The cardiology segment is expected to account for the fastest growth rate of around 28.01% during the forecast period.
  • The e-prescribing market is dominant in North America, which accounted for about 44.05% share of global revenue in 2022.
  • Europe is the second-largest market for e-prescription software.
  • Asia Pacific region is anticipated to demonstrate the fastest growth of around 30.11% during the forecast period.

Report Scope of the E-Prescribing Market

Report Coverage Details
Market Size in 2022 USD 2.9 billion
Revenue Forecast by 2032 USD 31.23 billion
Growth rate from 2023 to 2032 CAGR of 26.83%
Base Year 2022
Forecast Period 2023 to 2032
Regions Covered North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Covered Cerner Corporation (Oracle); Allscripts Healthcare LLC; Epic Systems Corporation; DrFirst; Athenahealth; NXGN Management LLC; McKesson Corporation; Surescripts; Change Healthcare; Practice Fusion, Inc.; Networking Technology, Inc. (RXNT)

 

Increasing adoption of electronic prescribing for controlled substances (EPSC) coupled with favorable government policies is expected to boost the market growth. At the federal level, the SUPPORT for Patients and Communities Act (H.R. 6), which Congress passed in October 2018, requires the use of electronic prescriptions for all controlled substances under Medicare Part D by January 1, 2021. Furthermore, rising awareness regarding patient safety is also anticipated to fuel market growth. During the COVID-19 pandemic, healthcare facilities were compelled to change their methods of providing their services to help curb the spread of infection among the general public and healthcare professionals. The demand for e-prescribing solutions increased, as it showed potential for improving access to prescription medicines as well as being convenient for patients. Market players also witnessed tremendous growth during the pandemic. For instance, Surescripts’ total number of e-Prescriptions exceeded 1 million prescribers in 2020.

New expansion activities, product approvals, product launches, partnerships, and acquisitions have positively impacted the e-prescribing market in recent years. For instance, in August 2021, Meddo, an India-based health startup, acquired Doxper, an e-prescription platform, which was founded in 2015 and deals in health record management and patient engagement solutions. Moreover, the market experienced a significant increase in the demand for e-prescription apps due to the growing digitalization, which in turn is fueling the market growth.

Electronic prescribing of controlled substances is now allowed in almost every state in the U.S. and Europe. The American Academy of Family Physicians (AAFP) has advocated for increased ease of EPCS implementation, and this process is improving. According to the World Health Organization, as of August 2021, around 70% of all drug use deaths are related to opioids and 30% are due to overdose. The opioid crisis in countries such as the U.S. is a major point of concern, which is expected to drive the demand for technologies such as e-prescribing. EPCS provides a secure, transparent system that makes it easier to prescribe controlled substances to patients who legitimately need them while making it more difficult to commit fraud or abuse.

Regional Insights

The e-prescribing market is dominant in North America, which accounted for about 44.02% share of global revenue in 2022. The major factor contributing to the growth of this region is the high number of government initiatives and incentives in the region. Europe is the second-largest market for e-prescription software, owing to the strict regulatory policies in European countries to prevent medical errors. Furthermore, initiatives by the EU are further anticipated to lead to regional growth.

While many countries do not accept e-prescriptions from other countries, the EU issued a circular in 2019 allowing the use of an e-prescription issued by a practitioner in a different country while visiting a pharmacy in another EU country. Asia Pacific region is anticipated to demonstrate the fastest growth of around 30.1% during the forecast period. This growth can be attributed to an increase in the penetration of technology and rising disposable income in the region.

E-Prescribing Market Segmentations:

By Product

  • Solutions
    • Integrated Solutions
    • Standalone Solutions
  • Services
    • Support
    • Implementation
    • Training
    • Network

By Delivery Mode

  • Web/Cloud-Based
  • On-premise

By End-use

  • Hospital
  • Office-based Physicians
  • Pharmacy

By Usage Methods

  • Handheld
  • Computer Based Devices

By Substances

  • Controlled Substances
  • Non-controlled Substances

By Specialties

  • Oncology
  • Sports Medicine
  • Neurology
  • Cardiology
  • Others

Frequently Asked Questions

The global e-prescribing market size was reached at USD 2.9 billion in 2022 and it is projected to hit around USD 31.23 billion by 2032.

The global e-prescribing market is growing at a compound annual growth rate (CAGR) of 26.83% from 2023 to 2032.

The Europe region has accounted for the largest e-prescribing market share in 2022.

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Specialties Procurement Analysis 

4.3.2. Sales and Distribution Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on E-Prescribing Market 

5.1. COVID-19 Landscape: E-Prescribing Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global E-Prescribing Market, By Product

8.1. E-Prescribing Market, by Product, 2023-2032

8.1.1. Solutions

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Services

8.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global E-Prescribing Market, By Delivery Mode

9.1. E-Prescribing Market, by Delivery Mode, 2023-2032

9.1.1. Web/Cloud-Based

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. On-premise

9.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global E-Prescribing Market, By End-use

10.1. E-Prescribing Market, by End-use, 2023-2032

10.1.1. Hospital

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Office-based Physicians

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Pharmacy

10.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global E-Prescribing Market, By Usage Methods

11.1. E-Prescribing Market, by Usage Methods, 2023-2032

11.1.1. Handheld

11.1.1.1. Market Revenue and Forecast (2020-2032)

11.1.2. Computer Based Devices

11.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 12. Global E-Prescribing Market, By Substances

12.1. E-Prescribing Market, by Substances, 2023-2032

12.1.1. Controlled Substances

12.1.1.1. Market Revenue and Forecast (2020-2032)

12.1.2. Non-controlled Substances

12.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 13. Global E-Prescribing Market, By Specialties

13.1. E-Prescribing Market, by Specialties, 2023-2032

13.1.1. Oncology

13.1.1.1. Market Revenue and Forecast (2020-2032)

13.1.2. Sports Medicine

13.1.2.1. Market Revenue and Forecast (2020-2032)

13.1.3. Neurology

13.1.3.1. Market Revenue and Forecast (2020-2032)

13.1.4. Cardiology

13.1.4.1. Market Revenue and Forecast (2020-2032)

13.1.5. Others

13.1.5.1. Market Revenue and Forecast (2020-2032)

Chapter 14. Global E-Prescribing Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Forecast, by Product (2020-2032)

14.1.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)

14.1.3. Market Revenue and Forecast, by End-use (2020-2032)

14.1.4. Market Revenue and Forecast, by Usage Methods (2020-2032)

14.1.5. Market Revenue and Forecast, by Substances (2020-2032)

14.1.6. Market Revenue and Forecast, by Specialties (2020-2032)

14.1.7. U.S.

14.1.7.1. Market Revenue and Forecast, by Product (2020-2032)

14.1.7.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)

14.1.7.3. Market Revenue and Forecast, by End-use (2020-2032)

14.1.7.4. Market Revenue and Forecast, by Usage Methods (2020-2032)

14.1.8. Market Revenue and Forecast, by Substances (2020-2032)

14.1.8.1. Market Revenue and Forecast, by Specialties (2020-2032) 

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Forecast, by Product (2020-2032)

14.1.9.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)

14.1.9.3. Market Revenue and Forecast, by End-use (2020-2032)

14.1.9.4. Market Revenue and Forecast, by Usage Methods (2020-2032)

14.1.10. Market Revenue and Forecast, by Substances (2020-2032)

14.1.11. Market Revenue and Forecast, by Specialties (2020-2032)

14.1.11.1.

14.2. Europe

14.2.1. Market Revenue and Forecast, by Product (2020-2032)

14.2.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)

14.2.3. Market Revenue and Forecast, by End-use (2020-2032)

14.2.4. Market Revenue and Forecast, by Usage Methods (2020-2032) 

14.2.5. Market Revenue and Forecast, by Substances (2020-2032)

14.2.6. Market Revenue and Forecast, by Specialties (2020-2032)

14.2.7.

14.2.8. UK

14.2.8.1. Market Revenue and Forecast, by Product (2020-2032)

14.2.8.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)

14.2.8.3. Market Revenue and Forecast, by End-use (2020-2032)

14.2.9. Market Revenue and Forecast, by Usage Methods (2020-2032) 

14.2.10. Market Revenue and Forecast, by Substances (2020-2032)

14.2.10.1. Market Revenue and Forecast, by Specialties (2020-2032) 

14.2.11. Germany

14.2.11.1. Market Revenue and Forecast, by Product (2020-2032)

14.2.11.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)

14.2.11.3. Market Revenue and Forecast, by End-use (2020-2032)

14.2.12. Market Revenue and Forecast, by Usage Methods (2020-2032)

14.2.13. Market Revenue and Forecast, by Substances (2020-2032)

14.2.14. Market Revenue and Forecast, by Specialties (2020-2032)

14.2.14.1.

14.2.15. France

14.2.15.1. Market Revenue and Forecast, by Product (2020-2032)

14.2.15.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)

14.2.15.3. Market Revenue and Forecast, by End-use (2020-2032)

14.2.15.4. Market Revenue and Forecast, by Usage Methods (2020-2032)

14.2.16. Market Revenue and Forecast, by Substances (2020-2032)

14.2.16.1. Market Revenue and Forecast, by Specialties (2020-2032)

14.2.17. Rest of Europe

14.2.17.1. Market Revenue and Forecast, by Product (2020-2032)

14.2.17.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)

14.2.17.3. Market Revenue and Forecast, by End-use (2020-2032)

14.2.17.4. Market Revenue and Forecast, by Usage Methods (2020-2032)

14.2.18. Market Revenue and Forecast, by Substances (2020-2032)

14.2.18.1. Market Revenue and Forecast, by Specialties (2020-2032)

14.3. APAC

14.3.1. Market Revenue and Forecast, by Product (2020-2032)

14.3.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)

14.3.3. Market Revenue and Forecast, by End-use (2020-2032)

14.3.4. Market Revenue and Forecast, by Usage Methods (2020-2032)

14.3.5. Market Revenue and Forecast, by Substances (2020-2032)

14.3.6. Market Revenue and Forecast, by Specialties (2020-2032)

14.3.7. India

14.3.7.1. Market Revenue and Forecast, by Product (2020-2032)

14.3.7.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)

14.3.7.3. Market Revenue and Forecast, by End-use (2020-2032)

14.3.7.4. Market Revenue and Forecast, by Usage Methods (2020-2032)

14.3.8. Market Revenue and Forecast, by Substances (2020-2032)

14.3.9. Market Revenue and Forecast, by Specialties (2020-2032)

14.3.10. China

14.3.10.1. Market Revenue and Forecast, by Product (2020-2032)

14.3.10.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)

14.3.10.3. Market Revenue and Forecast, by End-use (2020-2032)

14.3.10.4. Market Revenue and Forecast, by Usage Methods (2020-2032)

14.3.11. Market Revenue and Forecast, by Substances (2020-2032)

14.3.11.1. Market Revenue and Forecast, by Specialties (2020-2032)

14.3.12. Japan

14.3.12.1. Market Revenue and Forecast, by Product (2020-2032)

14.3.12.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)

14.3.12.3. Market Revenue and Forecast, by End-use (2020-2032)

14.3.12.4. Market Revenue and Forecast, by Usage Methods (2020-2032)

14.3.12.5. Market Revenue and Forecast, by Substances (2020-2032)

14.3.12.6. Market Revenue and Forecast, by Specialties (2020-2032)

14.3.13. Rest of APAC

14.3.13.1. Market Revenue and Forecast, by Product (2020-2032)

14.3.13.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)

14.3.13.3. Market Revenue and Forecast, by End-use (2020-2032)

14.3.13.4. Market Revenue and Forecast, by Usage Methods (2020-2032)

14.3.13.5. Market Revenue and Forecast, by Substances (2020-2032)

14.3.13.6. Market Revenue and Forecast, by Specialties (2020-2032)

14.4. MEA

14.4.1. Market Revenue and Forecast, by Product (2020-2032)

14.4.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)

14.4.3. Market Revenue and Forecast, by End-use (2020-2032)

14.4.4. Market Revenue and Forecast, by Usage Methods (2020-2032)

14.4.5. Market Revenue and Forecast, by Substances (2020-2032)

14.4.6. Market Revenue and Forecast, by Specialties (2020-2032)

14.4.7. GCC

14.4.7.1. Market Revenue and Forecast, by Product (2020-2032)

14.4.7.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)

14.4.7.3. Market Revenue and Forecast, by End-use (2020-2032)

14.4.7.4. Market Revenue and Forecast, by Usage Methods (2020-2032)

14.4.8. Market Revenue and Forecast, by Substances (2020-2032)

14.4.9. Market Revenue and Forecast, by Specialties (2020-2032)

14.4.10. North Africa

14.4.10.1. Market Revenue and Forecast, by Product (2020-2032)

14.4.10.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)

14.4.10.3. Market Revenue and Forecast, by End-use (2020-2032)

14.4.10.4. Market Revenue and Forecast, by Usage Methods (2020-2032)

14.4.11. Market Revenue and Forecast, by Substances (2020-2032)

14.4.12. Market Revenue and Forecast, by Specialties (2020-2032)

14.4.13. South Africa

14.4.13.1. Market Revenue and Forecast, by Product (2020-2032)

14.4.13.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)

14.4.13.3. Market Revenue and Forecast, by End-use (2020-2032)

14.4.13.4. Market Revenue and Forecast, by Usage Methods (2020-2032)

14.4.13.5. Market Revenue and Forecast, by Substances (2020-2032)

14.4.13.6. Market Revenue and Forecast, by Specialties (2020-2032)

14.4.14. Rest of MEA

14.4.14.1. Market Revenue and Forecast, by Product (2020-2032)

14.4.14.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)

14.4.14.3. Market Revenue and Forecast, by End-use (2020-2032)

14.4.14.4. Market Revenue and Forecast, by Usage Methods (2020-2032)

14.4.14.5. Market Revenue and Forecast, by Substances (2020-2032)

14.4.14.6. Market Revenue and Forecast, by Specialties (2020-2032)

14.5. Latin America

14.5.1. Market Revenue and Forecast, by Product (2020-2032)

14.5.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)

14.5.3. Market Revenue and Forecast, by End-use (2020-2032)

14.5.4. Market Revenue and Forecast, by Usage Methods (2020-2032)

14.5.5. Market Revenue and Forecast, by Substances (2020-2032)

14.5.6. Market Revenue and Forecast, by Specialties (2020-2032)

14.5.7. Brazil

14.5.7.1. Market Revenue and Forecast, by Product (2020-2032)

14.5.7.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)

14.5.7.3. Market Revenue and Forecast, by End-use (2020-2032)

14.5.7.4. Market Revenue and Forecast, by Usage Methods (2020-2032)

14.5.8. Market Revenue and Forecast, by Substances (2020-2032)

14.5.8.1. Market Revenue and Forecast, by Specialties (2020-2032)

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Forecast, by Product (2020-2032)

14.5.9.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)

14.5.9.3. Market Revenue and Forecast, by End-use (2020-2032)

14.5.9.4. Market Revenue and Forecast, by Usage Methods (2020-2032)

14.5.9.5. Market Revenue and Forecast, by Substances (2020-2032)

14.5.9.6. Market Revenue and Forecast, by Specialties (2020-2032)

Chapter 15. Company Profiles

15.1. Cerner Corporation (Oracle)

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. Allscripts Healthcare LLC

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. Epic Systems Corporation

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. DrFirst

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. Athenahealth

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. NXGN Management LLC

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. McKesson Corporation

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. Surescripts

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. Change Healthcare

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. Practice Fusion, Inc.

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers